FDA approves dabrafenib–trametinib for BRAF-positive cancers
WEBJul 21, 2022 · The Food and Drug Administration (FDA) recently approved the combination of the targeted drugs dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of people with nearly any type of advanced solid tumor that has a specific mutation in a …
News - Baton Rouge Area Foundation
WEBBaton Rouge, LA – The Baton Rouge Area Foundation (BRAF) today announced the release of the 15th iteration of its CityStats report, a survey assessing key indicators to gauge quality of life and access to opportunity in East Baton Rouge Parish. This year’s report reveals that there has been a positive shift in the community’s […]
BRAF — a tumour-agnostic drug target with lineage-specific
WEBJan 26, 2024 · Introduction. Oncogenic BRAF mutations induce MAPK signalling pathway activation and are key drivers of tumorigenesis across diverse cancer types, including melanomas, thyroid cancers, colorectal...
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically …
WEBNEW YORK, September 14, 2024 -- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and...
Pfizer pushing BRAF lung cancer mutation testing to grow market …
WEBNEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N) is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical...
Immunotherapy Combination for BRAF+ Melanoma - NCI
WEBDec 17, 2021 · More patients with advanced melanoma with BRAF mutations (BRAF+) treated first with the immunotherapy drugs ipilimumab (Yervoy) and nivolumab (Opdivo) were alive after 2 years than patients treated with the targeted therapies dabrafenib (Tafinlar) and trametinib (Mekinist), according to results of the DREAMseq trial.
A new BRAF inhibitor breaks resistance barriers - Cell Press
WEBJun 11, 2024 · A next-generation BRAF inhibitor overcomes resistance to BRAF inhibition in patients with BRAF-mutant cancers using pharmacokinetics-informed dose escalation
Novartis bags FDA okay for BRAF-positive tumour combination
WEB3 days ago · Novartis' two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E mutation – regardless of where they occur in the...
New directions in targeting the multifaceted BRAF in cancer
WEBAug 12, 2024 · In cancer patients, BRAF-targeting precision therapeutics are effective against Class I BRAF alterations (p.V600 hotspot mutations) in tumors such as melanoma, thyroid cancer, and colorectal...
Baton Rouge Area Foundation | Partners in Philanthropy & Civic …
WEBNews. Get the latest BRAF headlines and engage with stories about our organization and our community. View News. How to get involved. There are countless ways to help spread the spirit of giving in Baton Rouge.